Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings.
rct · Level I
Where this comes from
- Record sourced from PubMed, PMID 40888096.
- Also identified by DOI 10.1093/cid/ciaf477 and PMC identifier 12477884.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We performed a win ratio (WR) analysis of REPRIEVE, a randomized trial of pitavastatin vs placebo for cardiovascular disease in people with human immunodeficiency virus to assess robustness to event severity. WR aligns with primary findings and provides insight into pitavastatin protections: persistent advantage on death, stroke, and myocardial infarction. Clinical Trials Registration . NCT02344290.
Medical subject headings
- Quinolines
- HIV Infections
- Cardiovascular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors